ReviewHeliyon2022
Recent advances in functionalization of nanotextiles: A strategy to combat harmful microorganisms and emerging pathogens in the 21
Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Effective Antibacterial Medical Mask Based on the Novel Biosynthesized Copper Nanoparticles (CuNPs).International journal of microbiology · 2026Article
- Advances in combating antimicrobial resistance in MRSA: a comprehensive review on nanotechnology and phage therapy.Antonie van Leeuwenhoek · 2025Review
- Scalable Fabrication of Core-Sheath Nanofiber Yarns via NanoTwist Spinning for High-Performance Energy-HarvestingACS applied materials & interfaces · 2025Article
- Zinc Oxide Nanoparticles in Modern Science and Technology: Multifunctional Roles in Healthcare, Environmental Remediation, and Industry.Nanomaterials (Basel, Switzerland) · 2025Review
- Advancing food safety with biogenic silver nanoparticles: Addressing antimicrobial resistance, sustainability, and commercial viability.Food chemistry: X · 2025Review
- Current knowledge for implementing safe and sustainable by design across the life cycle of nanosilver textiles.Discover sustainability · 2025Review
- A roadmap towards safe and sustainable by design nanotechnology: Implementation for nano-silver-based antimicrobial textile coatings production by ASINA project.Computational and structural biotechnology journal · 2024Article
- Recent Advancements in Acrylic Fabric Applications: A Comprehensive Review and Future Trends.Polymers · 2024Review
- Development of Smart Clothing to Prevent Pressure Injuries in Bedridden Persons and/or with Severely Impaired Mobility: 4NoPressure Research Protocol.Healthcare (Basel, Switzerland) · 2023Article
- Ag-Decorated Iron Oxides-Silica Magnetic Nanocomposites with Antimicrobial and Photocatalytic Activity.Nanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The textile industry can benefit from nanotechnology as new properties are conferred on functionalized nanotextiles beyond what a fabric can traditionally offer. These properties include extermination of microorganisms by nanotextiles to curtail their growth and dissemination in the environment and in healthcare facilities. The emergence and thriving of multi-drug resistance (MDR) phenomenon among microbes are threats at achieving good health and well-being (goal 3) of sustainable development goals (SDG) of UN. In addition, MDR strains emerge at a higher rate than the frequency of discovery and production of potent antimicrobial drugs. Therefore, there is need for innovative approach to tackle MDR. Among recent innovations is functionalization of textiles with metal nanoparticles to kill microorganisms. This paper explores strategies in nanotextile production to combat emerging diseases in the 21
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.